The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Arvinas, Inc. (ARVN) has been on a downward spiral lately with significant selling pressure. After declining 25.4% over the past four weeks, the stock looks well positioned for a trend reversal as ...

Arvinas, Inc. (NASDAQ:ARVN) develops treatments that break down disease-causing proteins using its PROTAC (Proteolysis Targeting Chimera) technology. The company’s main drugs target prostate ...

Gossamer Bio, Inc. (NASDAQ:GOSS) develops targeted treatments for pulmonary arterial hypertension (PAH) and other serious conditions. This clinical-stage biotech company has its leading drug ...

Highlights,Vanguard Group Inc. expanded its ownership in Arvinas, holding over a tenth of the company's shares.,Institutional investors such as KBC Group NV and the Teacher Retirement System of Texas ...

ARVN opened at $6.37 on Monday. The firm has a market cap of $438.08 million, a PE ratio of -2.30 and a beta of 2.30. The stock has a 50-day moving average price of $13.91 and a 200-day moving ...

In a report released today, Michael Schmidt from Guggenheim maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report), with a price target of $32.00. The company’s shares ...

In a report released today, Edward Tenthoff from Piper Sandler maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report), with a price target of $24.00. The company’s shares ...

Arvinas, Inc. (NASDAQ:ARVN – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the fifteen brokerages that are currently covering the company, MarketBeat reports.

The loss by the Army of the Republic of Vietnam (ARVN) underscored the total dependence of the Saigon government on direct American military intervention, which had been withdrawn as a result of ...